Von Willebrand disease

Last updated
von Willebrand disease
Autosomal dominant - en.svg
von Willebrand disease types I and II are inherited in an autosomal dominant pattern.
Pronunciation
Specialty Hematology

Von Willebrand disease (VWD) is the most common hereditary blood-clotting disorder in humans. An acquired form can sometimes result from other medical conditions. [1] It arises from a deficiency in the quality or quantity of von Willebrand factor (VWF), a multimeric protein that is required for platelet adhesion. It is known to affect several breeds of dogs as well as humans. The three forms of VWD are hereditary, acquired, and pseudo or platelet type. The three types of hereditary VWD are VWD type 1, VWD type 2, and VWD type 3. Type 2 contains various subtypes. [2] Platelet type VWD is also an inherited condition. [3]

Contents

In 2008 a new diagnostic category of "Low VWF" was proposed to include those individuals whose von Willebrand factor levels were in the 30–50 IU/dL range, below the normal reference range but not low enough to be von Willebrand disease. [4] Patients with low VWF were sometimes noted to experience bleeding, despite mild reductions in VWF levels. [5] The 2021 ASH/ISTH guidelines re-classified patients with levels in the 30–50 IU/dl range as "Low VWF" if they have no bleeding, but as having VWD if they have bleeding. [6]

VWD type 1 is the most common type of the disorder, with mild bleeding symptoms such as nosebleeds, though occasionally more severe symptoms can occur. Blood type can affect the presentation and severity of symptoms of VWD. [7]

VWD type 2 is the second most common type of the disorder and has mild to moderate symptoms.

The factor is named after the Finnish physician Erik Adolf von Willebrand who first described the condition in 1926. Guidelines for the diagnosis and management of VWD were updated in 2021. [6] [8]

Signs and symptoms

The various types of VWD present with varying degrees of bleeding tendency, usually in the form of easy bruising, nosebleeds, and bleeding gums. [2] Women may experience heavy menstrual periods and blood loss during childbirth. [9] [10]

Severe internal bleeding and bleeding into joints are uncommon in all but the most severe type, VWD type 3.

Genetics

The VWF gene is located on the short arm p of chromosome 12 (12p13.2). It has 52 exons spanning 178 kbp. Types 1 and 2 are inherited as autosomal dominant traits. Occasionally, type 2 also inherits recessively. Type 3 is inherited as autosomal recessive. However, some individuals heterozygous for type 3 may be diagnosed with VWD type 1, indicating an intermediate inheritance in those cases. VWD occurs in approximately 1% of the population and affects men and women equally. [11]

Genetic testing is typically not part of the initial workup for von Willebrand disease, and is not needed for people diagnosed with type 1 VWD based on clinical history and laboratory tests. [12] It is mainly useful for: [12]

Pathophysiology

Von Willebrand factor is mainly active in conditions of high blood flow and shear stress. Deficiency of VWF, therefore, shows primarily in organs with extensive small vessels, such as skin, gastrointestinal tract, and uterus. In angiodysplasia, a form of telangiectasia of the colon, shear stress is much higher than in average capillaries, and the risk of bleeding is increased concomitantly. [13]

In more severe cases of type 1 VWD, genetic changes are common within the VWF gene and are highly penetrant. In milder cases of type 1 VWD, a complex spectrum of molecular pathology may exist in addition to polymorphisms of the VWF gene alone. [14]

The individual's ABO blood group can influence presentation and pathology of VWD. Those individuals with blood group O have a lower mean level than individuals with other blood groups. Unless ABO group-specific VWF:antigen reference ranges are used, normal group O individuals can be diagnosed as type I VWD, and some individuals of blood group AB with a genetic defect of VWF may have the diagnosis overlooked because VWF levels are elevated due to blood group. [15]

Diagnosis

Basic tests performed in any patient with bleeding problems are a complete blood count-CBC (especially platelet counts), activated partial thromboplastin time-APTT, prothrombin time with International Normalized Ratio-PTINR, thrombin time-TT, and fibrinogen level. Patients with abnormal tests typically undergo further testing for hemophilias. Other coagulation factor assays may be performed depending on the results of a coagulation screen. Patients with von Willebrand disease typically display a normal prothrombin time and a variable prolongation of APTT, depending on whether sufficient VWF is available to perform its carrier function for factor VIII. [6]

When VWD is suspected, blood plasma of a patient must be investigated for quantitative and qualitative deficiencies of VWF. This is achieved by measuring the amount of VWF in a VWF antigen assay and the functionality of VWF with a glycoprotein (GP)Ib binding assay, VWF antibody assay, or a ristocetin cofactor activity (RiCof) assay. [16] Factor VIII levels are also performed because factor VIII is bound to VWF which protects the factor VIII from rapid breakdown within the blood. Deficiency of VWF can then lead to a reduction in factor VIII levels, which explains the elevation in PTT. Normal levels do not exclude all forms of VWD, particularly type 2, which may only be revealed by investigating platelet interaction with subendothelium under flow, a highly specialized coagulation study not routinely performed in most medical laboratories. Ristocetin-induced platelet agglutination (RIPA), collagen binding, and/or VWF multimer assays may be performed to follow up abnormal screening tests. A platelet aggregation assay will show an abnormal response to ristocetin with normal responses to the other agonists used:

Platelet aggregation function by main disorders and agonists   edit
Further information: Platelet § Tests of function
ADP Epinephrine Collagen Ristocetin
P2Y receptor inhibitor or defect [17] DecreasedNormalNormalNormal
Adrenergic receptor defect [17] NormalDecreasedNormalNormal
Collagen receptor defect [17] NormalNormalDecreased or absentNormal
NormalNormalNormalDecreased or absent
DecreasedDecreasedDecreasedNormal or decreased

A platelet function assay may give an abnormal collagen/epinephrine closure time, and in most cases, a normal collagen/ADP time. Type 2N may be considered if factor VIII levels are disproportionately low, but confirmation requires a "factor VIII binding" assay. Additional laboratory tests that help classify sub-types of VWD include von Willebrand multimer analysis, modified ristocetin induced platelet aggregation assay and VWF propeptide to VWF propeptide antigen ratio. In cases of suspected acquired von Willebrand syndrome, a mixing study (analysis of patient plasma along with pooled normal plasma/PNP and a mixture of the two tested immediately, at one hour, and at two hours) should be performed. [18] Detection of VWD is complicated by VWF being an acute-phase reactant with levels rising in infection, pregnancy, and stress.

The testing for VWD can be influenced by laboratory procedures. Numerous variables exist in the testing procedure that may affect the validity of the test results and may result in a missed or erroneous diagnosis. The chance of procedural errors are typically greatest during the preanalytical phase (during collecting storage and transportation of the specimen) especially when the testing is contracted to an outside facility and the specimen is frozen and transported long distances. [19] Diagnostic errors are not uncommon, and the rate of testing proficiency varies amongst laboratories, with error rates ranging from 7 to 22% in some studies to as high as 60% in cases of misclassification of VWD subtype. To increase the probability of a proper diagnosis, testing should be done at a facility with immediate on-site processing in a specialized coagulation laboratory. [20] [21]

Types

Pie chart of relative incidences of von Willebrand disease types in South Africa. Platelet-type was <0.5% of cases. Pie chart of relative incidences of Von Willebrand disease types.jpg
Pie chart of relative incidences of von Willebrand disease types in South Africa. Platelet-type was <0.5% of cases.

The four hereditary types of VWD described are type 1, type 2, type 3, and pseudo- or platelet-type. Most cases are hereditary, but acquired forms of VWD have been described. The International Society on Thrombosis and Haemostasis's classification depends on the definition of qualitative and quantitative defects. [6]

von Willebrand disease type III (and sometimes II) is inherited in an autosomal recessive pattern. Autorecessive.svg
von Willebrand disease type III (and sometimes II) is inherited in an autosomal recessive pattern.

Type 1

Type 1 VWD (40 [22] -80% [11] of all VWD cases) is a quantitative defect which is heterozygous for the defective gene. It arises from failure to secrete VWF into the circulation or, in the case of Type 1C, from VWF being cleared more quickly than normal. If VWF levels are greater than 50%, VWD can be ruled out. If VWF activity is below 30%, VWD is present. Patients with VWF activity between 0.30-0.50 IU/mL are classified based on their bleeding phenotype. If they have bleeding symptoms, they have VWD. If they have no bleeding, they are considered to have "Low VWF". [6]

Many patients are asymptomatic or may have mild symptoms and not have clearly impaired clotting, which might suggest a bleeding disorder. Often, the discovery of low VWF occurs incidentally to other medical procedures requiring a blood work-up. Most cases of low VWF are never diagnosed due to its asymptomatic or mild presentation, and most people with type I VWD end up leading a normal life free of complications, with many being unaware that they have the disorder.

Trouble may, however, arise in some patients in the form of bleeding following surgery (including dental procedures), noticeable easy bruising, or menorrhagia (heavy menstrual periods). The minority of cases of type 1 may present with severe hemorrhagic symptoms.

Type 1C

Type 1C VWD indicates patients with quantitative deficiency due to an enhanced VWF clearance, accounting for ∼15% to 20% of cases. Such patients may require VWF concentrate to treat/prevent bleeds. [23] [6]

Type 2

Type 2 VWD (15 [11] -50% [22] of cases) is a qualitative defect and the bleeding tendency can vary between individuals. Four subtypes exist: 2A, 2B, 2M, and 2N. These subtypes depend on the presence and behavior of the underlying multimers. [11] Type 2 VWD (other than 2N) features an activity-to-antigen ratio of less than 0.7. [6] This ratio is obtained by dividing the VWF activity by the VWF antigen.

Type 2A

VWD Type 2A results from a loss-of-function mutation in von Willebrand factor (VWF), leading to reduced binding of VWF with Platelet GP1b receptors. This disorder follows an autosomal dominant inheritance pattern with only occasional cases following autosomal recessive pattern. It accounts for 10-15% of all VWD cases. It manifests with moderate to moderately severe bleeding. Diagnostic features of VWD Type 2A include greater reduction in VWF activity (measured by a functional assay) compared to VWF antigen (quantity). This results in a decreased VWF Activity to Antigen ratio. Additionally, high molecular weight multimers are either absent or very low on electrophoresis due to impaired multimer assembly or increased susceptibility to ADAMTS13 (a protease that cleaves VWF). Factor VIII activity can be normal or low. Ristocetin-induced platelet aggregation (RIPA) is typically low.

Type 2B

This is a "gain of function" defect. The ability of the qualitatively defective VWF to bind to glycoprotein Ib (GPIb) receptor on the platelet membrane is abnormally enhanced, leading to its spontaneous binding to platelets and subsequent rapid clearance of the bound platelets and of the large VWF multimers. Thrombocytopenia may occur. Large VWF multimers are reduced or absent from the circulation. [6]

The ristocetin cofactor activity is low when the patient's platelet-poor plasma is assayed against formalin-fixed, normal donor platelets. However, when the assay is performed with the patient's own platelets (platelet-rich plasma), a lower-than-normal amount of ristocetin causes aggregation to occur. This is due to the large VWF multimers remaining bound to the patient's platelets. Patients with this subtype are unable to use desmopressin as a treatment for bleeding, because it can lead to unwanted platelet aggregation and aggravation of thrombocytopenia. [24]

Type 2M

VWD Type 2M results from a loss-of-function mutation in von Willebrand factor (VWF). This mutation leads to reduced binding of VWF with GP1b (similar to VWD Type 2A) or with collagen. Like other Type 2 VWD subtypes, there is a decreased ratio of VWF Activity to antigen. Differentiating VWD Type 2M from Type 2A involves analyzing VWF multimers through electrophoresis. In VWD Type 2M, all multimers are identified but uniformly decreased in quantity, resembling the pattern seen in VWD Type 1. Conversely, in VWD Type 2A, high molecular weight multimers are either absent or present in very low quantities. VWD Type 2M can be further differentiated from VWD Type 1 based on the VWF Activity to antigen ratio. In Type 1, the ratio is >0.7. [6] In Type 2M, the ratio is <0.7. In Type 2M, factor VIII activity can be normal or low while the ristocetin-induced platelet aggregation (RIPA) is typically low. It is uncommon and manifests with moderate to severe bleeding. The disease may follow either an autosomal dominant or recessive pattern of inheritance.

Type 2N (Normandy)

Type 2N VWD results from a loss-of-function mutation that reduces the binding of von Willebrand factor (VWF) to factor VIII. Although VWF antigen (quantity) and activity levels (Ristocetin cofactor assay) remain normal, factor VIII levels are typically low (usually 5-15%) due to impaired VWF binding. This vulnerability to proteolysis in the circulation leads to clinical manifestations resembling those of Hemophilia A. The significantly reduced factor VIII levels in VWD Type 2N can sometimes lead to misdiagnosis as mild Hemophilia A. Like Hemophilia A, VWD Type 2N presents with joint and soft tissue bleeds. It is an autosomal recessive disorder, requiring either homozygosity or double heterozygosity for disease manifestation. Diagnostic tools include assessing the ratio of VWF binding to VWF antigen levels. [25] A ratio <0.3 indicates homozygous or double heterozygous VWD Type 2N, while a ratio <0.5 suggests heterozygous VWD Type 2N. Conversely, a VWF antigen-to-binding ratio >3 confirms the diagnosis of VWD Type 2N. Ristocetin-Induced Platelet Agglutination (RIPA) and VWF multimer analysis are typically normal.

Type 3

VWD type 3 is a rare but the most severe form of VWD. It occurs in individuals who are homozygous for the defective gene, resulting in a severe quantitative deficiency or complete absence of von Willebrand factor (VWF) production. In VWD type 3, VWF is undetectable in the VWF antigen assay. Since VWF normally protects coagulation factor VIII from proteolytic degradation, the total absence of VWF leads to extremely low factor VIII levels (typically 1-10%). These low levels are equivalent to those seen in severe hemophilia A, with clinical manifestations of life-threatening external and internal hemorrhages. The inheritance pattern of VWD type 3 is autosomal recessive, meaning that both parents must carry the defective gene for their child to be affected. In contrast, hemophilia A follows an X-linked recessive inheritance pattern. Additional diagnostic tools for VWD type 3 include assessing VWF activity using the Ristocetin cofactor assay and Collagen binding assay. In VWD type 3, VWF activity is either absent or approaching undetectable. VWF multimer analysis reveals no bands or very faint bands on electrophoresis. Additionally, Ristocetin-Induced Platelet Agglutination (RIPA) is typically absent or severely low.

Comparison

Von Willebrand disease types [26]
Mechanism Autosomal inheritancevWF activity RIPA Multimer quantity
Type 1Decreased VWF quantityDominantDecreasedNormal [12] or decreased [26] Similar decrease among multimer types
Type 2AInability to form large multimersDominant or recessiveDecreasedOften decreased at high ristocetin concentrations [12] Decreased large multimers
BEnhanced binding to GPIb receptorDominantDecreasedIncreasedDecreased large multimers
MDecreased binding to GPIb receptorDominant or recessiveDecreasedDecreased at high ristocetin concentrations [12] Similar decrease among multimer types
NDecreased binding to factor VIII RecessiveNormalNormalNormal
Type 3Absent VWFRecessiveAbsent or markedly decreasedAbsent or markedly decreasedUsually undetectable

Platelet-type

Platelet-type VWD (also known as pseudo-VWD) is an autosomal dominant genetic defect of the platelets. The VWF is qualitatively normal and genetic testing of the von Willebrand gene and VWF protein reveals no mutational alteration. The defect lies in the qualitatively altered GPIb receptor on the platelet membrane which increases its affinity to bind to the VWF. Large platelet aggregates and high molecular weight VWF multimers are removed from the circulation resulting in thrombocytopenia and diminished or absent large VWF multimers. The ristocetin cofactor activity and loss of large VWF multimers are similar to VWD type 2B.

Acquired

Acquired Von Willebrand syndrome can occur due to autoantibodies, either interfering with platelet or collagen binding; increasing VWF clearance from the plasma; adsorption to myeloma cells or platelets; or proteolytic cleavage of VWF after shear stress-induced unfolding. [27]

A form of acquired VWD occurs in patients with aortic valve stenosis, leading to gastrointestinal bleeding (Heyde's syndrome). This form of acquired VWD may be more prevalent than is presently thought. In 2003, Vincentelli et al. noted that patients with acquired VWD and aortic stenosis who underwent valve replacement experienced a correction of their hemostatic abnormalities, but that the hemostatic abnormalities can recur after 6 months when the prosthetic valve is a poor match with the patient. [28] Similarly, acquired VWD contributes to the bleeding tendency in people with an implant of a left ventricular assist device (a pump that pumps blood from the left ventricle of the heart into the aorta). [29]

Treatment

For patients with VWD type 1 and VWD type 2A, desmopressin is available as different preparations, recommended for use in cases of minor trauma, or in preparation for dental or minor surgical procedures. Desmopressin stimulates the release of VWF from the Weibel–Palade bodies of endothelial cells, thereby increasing the levels of VWF (as well as coagulant factor VIII) three- to five-fold. Desmopressin is also available as a preparation for intranasal administration (Stimate) and as a preparation for intravenous administration. Desmopressin is contraindicated in VWD type 2b because of the risk of aggravated thrombocytopenia and thrombotic complications. Desmopressin is probably not effective in VWD type 2M and is rarely effective in VWD type 2N. It is totally ineffective in VWD type 3. [24]

For women with heavy menstrual bleeding, estrogen-containing oral contraceptive medications are effective in reducing the frequency and duration of the menstrual periods. Estrogen and progesterone compounds available for use in the correction of menorrhagia include ethinylestradiol,levonorgestrel, drospirenone and cyproterone. Administration of ethinylestradiol diminishes the secretion of luteinizing hormone and follicle-stimulating hormone from the pituitary, leading to stabilization of the endometrial surface of the uterus. [30]

Desmopressin is a synthetic analog of the natural antidiuretic hormone vasopressin. Its overuse can lead to water retention and dilutional hyponatremia with consequent convulsion. [31]

For patients with VWD scheduled for surgery and cases of VWD disease complicated by clinically significant hemorrhage, human-derived medium purity factor VIII concentrates, which also contain von Willebrand factors, are available for prophylaxis and treatment. Humate P, Alphanate, Wilate and Koate HP are commercially available for prophylaxis and treatment of VWD, and have varying levels of factor VIII. Products with higher VWF:RCo/FVIII ratios allow for more frequent dosing of VWF if needed, without the risk of accumulation to supranormal levels of FVIII. Recombinant factor VIII products contain insignificant quantity of VWF, so are not clinically useful as standalone therapy for VWD. [8]

Risks of thrombosis, development of alloantibodies, and allergic reactions including anaphylaxis must be considered when administering these preparations. Such risks have emerged as the main concerns in factor replacement therapies as infectious risks have diminished. [32]

Blood transfusions are given as needed to correct anemia and hypotension secondary to hypovolemia. Infusion of platelet concentrates is recommended for correction of hemorrhage associated with platelet-type VWD. [33]

Vonicog alfa is a recombinant von Willebrand factor that was approved for use in the United States in December 2015, and for use in the European Union in August 2018. [34] [35] If baseline factor VIII activity is >40%, rVWF may be administered as a standalone product when immediate response is needed, but if Factor VIII activity is <40% and immediate response is needed, rVWF must be administered in conjunction with FVIII replacement therapy. [36]

Epidemiology

The prevalence of VWD is about one in 100 individuals. [37] However, the majority of these people do not have symptoms. The prevalence of clinically significant cases is one per 10,000. [37] Because most forms are rather mild, they are detected more often in women, whose bleeding tendency shows during menstruation. It may be more severe or apparent in people with blood type O. [38]

History

In 1924, a 5-year-old girl from Föglö, Åland, Finland, was brought to the Deaconess Hospital in Helsinki, where she was seen by Finnish physician Erik Adolf von Willebrand. He ultimately assessed 66 members of her family and reported in a 1926 Swedish-language article that this was a previously undescribed bleeding disorder that differed from hemophilia. [39] He published another article on the disorder in 1931, in the German language, which attracted international attention in the disease. [40] The eponymous name was assigned to the disease between the late 1930s and the early 1940s, in recognition of von Willebrand's extensive research. [41]

In the 1950s, it became clear that a "plasma factor", factor VIII, was decreased in these persons and that Cohn fraction I-0 could correct both the plasma deficiency of FVIII and the prolonged bleeding time. Since this time, the factor causing the long bleeding time was called the "von Willebrand factor" in honor of Erik Adolf von Willebrand.

Variant forms of VWF were recognized in the 1970s, and these variations are now recognized as the result of synthesis of an abnormal protein. During the 1980s, molecular and cellular studies distinguished hemophilia A and VWD more precisely. Persons who had VWD had a normal FVIII gene on the X chromosome, and some had an abnormal VWF gene on chromosome 12. Gene sequencing identified many of these persons as having a VWF gene mutation. The genetic causes of milder forms of low VWF are still under investigation, and these forms may not always be caused by an abnormal VWF gene.

Other animals

VWD can also affect dogs, pigs, and mice. Furthermore, cases have been reported in cats, horses, cattle, and rabbits.

The causal mutation for VWD type 1 was identified in dogs of the breeds Doberman Pinscher, German Pinscher, Bernese Mountain Dog, Manchester Terrier, Kerry Blue Terrier, Cardigan Welsh Corgi, Poodle, Coton de Tulear, Drentse Patrijshond, Papillon, and Stabyhoun. Causal mutations for type 2 were identified in dogs of the breeds German Wirehaired Pointer, German Shorthaired Pointer, and Chinese Crested; and for type 3 in dogs of the breeds Kooikerhondje, Scottish Terrier and Shetland Sheepdog. In dogs affected by type 1 VWD, the causal mutation was the same across all breeds and the same mutation was also detected in some human VWD type 1 patients. In contrast, the mutations causing VWD type 3 in dogs are specific to each breed. Genetic screening is offered for known breeds. [42] [43]

In pigs, the causal mutation for VWD type 3 has also been identified. It is a large duplication within the VWF gene and causes serious damage to the gene function, so that virtually no VWF protein is produced. The clinical picture in pigs is most similar to that in humans with VWD type 3. Therefore, those pigs are valuable models for clinical and pharmacological research. [44]

Mice affected by VWD type 3 were produced by genetic engineering to obtain a small sized model for the human disease. In these strains, the VWF gene has been knocked out. [45]

In animals of other species affected by VWD, the causal mutations have not yet been identified.

Oral manifestations

In the case of severe deficiency, there may be spontaneous gingival bleeding, ecchymosis, and epistaxis. Symptoms of VWD include postoperative bleeding, bleeding after dental extraction, gingival bleeding, epistaxis and easy bruising. The intake of oral contraceptives as the first-line treatment for menorrhagia may lead to gingival enlargement and bleeding in women. [46]

Platelet or coagulation disorders with severely altered hemostasis can cause spontaneous gingival bleeding, as seen in conjunction with hyperplastic hyperemic gingival enlargements in leukemic patients. Deposition of hemosiderin and other blood degradation products on the tooth surfaces turning them brown can occur with continuous oral bleeding over long periods. [47]

The location of oral bleeds was as follows: labial frenum, 60%; tongue, 23%; buccal mucosa, 17% and gingiva and palate, 0.5%. Severe hemophilia will have most frequent bleeding occurrences, followed by moderate and then mild hemophilia. They mostly come from traumatic injuries. Bleeding will also be induced by iatrogenic factors and poor oral hygiene practices. The frequency of oral hemorrhage by location in people with deficiency of F VIII and F IX is: gingiva, 64%; dental pulp, 13%; tongue, 7.5%; lip, 7%; palate, 2% and buccal mucosa, 1%. [47]

Dental considerations

The protocols suggest the use of factor concentrate along with the use of local hemostatic techniques, such as suturing, and local measures, such as the use of oxidized cellulose, for example, Surgicel or fibrin glue in conjunction with post-operatively administered antifibrinolytic agents where appropriate. [48]

The use of any non-steroidal anti-inflammatory drug (NSAID) must be discussed beforehand with the patient's hematologist because of their effect on platelet aggregation. There are no restrictions regarding the type of local anaesthetic agent used although those with vasoconstrictors may provide additional local hemostasis. [48]

See also

Related Research Articles

<span class="mw-page-title-main">Haemophilia</span> Genetic disease involving blood clotting

Haemophilia, or hemophilia, is a mostly inherited genetic disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding. This results in people bleeding for a longer time after an injury, easy bruising, and an increased risk of bleeding inside joints or the brain. Those with a mild case of the disease may have symptoms only after an accident or during surgery. Bleeding into a joint can result in permanent damage while bleeding in the brain can result in long term headaches, seizures, or an altered level of consciousness.

<span class="mw-page-title-main">Haemophilia A</span> Medical condition

Haemophilia A is a blood clotting disorder caused by a genetic deficiency in clotting factor VIII, thereby resulting in significant susceptibility to bleeding, both internally and externally. This condition occurs almost exclusively in males born to carrier mothers due to X-linked recessive inheritance. Nevertheless, rare isolated cases do emerge from de novo (spontaneous) mutations.

<span class="mw-page-title-main">Haemophilia B</span> Genetic X-linked recessive bleeding disorder

Haemophilia B, also spelled hemophilia B, is a blood clotting disorder causing easy bruising and bleeding due to an inherited mutation of the gene for factor IX, and resulting in a deficiency of factor IX. It is less common than factor VIII deficiency.

<span class="mw-page-title-main">Coagulation</span> Process of formation of blood clots

Coagulation, also known as clotting, is the process by which blood changes from a liquid to a gel, forming a blood clot. It results in hemostasis, the cessation of blood loss from a damaged vessel, followed by repair. The process of coagulation involves activation, adhesion and aggregation of platelets, as well as deposition and maturation of fibrin.

<span class="mw-page-title-main">Factor VIII</span> Blood-clotting protein

Coagulation factor VIII is an essential blood clotting protein. In humans, it is encoded by F8 gene. Defects in this gene result in hemophilia A, an X-linked bleeding disorder.

<span class="mw-page-title-main">Heyde's syndrome</span> Medical condition

Heyde's syndrome is a syndrome of gastrointestinal bleeding from angiodysplasia in the presence of aortic stenosis.

von Willebrand factor Mammalian protein involved in blood clotting

Von Willebrand factor (VWF) is a blood glycoprotein that promotes hemostasis, specifically, platelet adhesion. It is deficient and/or defective in von Willebrand disease and is involved in many other diseases, including thrombotic thrombocytopenic purpura, Heyde's syndrome, and possibly hemolytic–uremic syndrome. Increased plasma levels in many cardiovascular, neoplastic, metabolic, and connective tissue diseases are presumed to arise from adverse changes to the endothelium, and may predict an increased risk of thrombosis.

Weibel–Palade bodies (WPBs) are the storage granules of endothelial cells, the cells that form the inner lining of the blood vessels and heart. They manufacture, store and release two principal molecules, von Willebrand factor and P-selectin, and thus play a dual role in hemostasis and inflammation.

<span class="mw-page-title-main">Bleeding diathesis</span> High tendency to bleed due to a blood clotting disorder

In medicine (hematology), bleeding diathesis is an unusual susceptibility to bleed (hemorrhage) mostly due to hypocoagulability, in turn caused by a coagulopathy. Therefore, this may result in the reduction of platelets being produced and leads to excessive bleeding. Several types of coagulopathy are distinguished, ranging from mild to lethal. Coagulopathy can be caused by thinning of the skin, such that the skin is weakened and is bruised easily and frequently without any trauma or injury to the body. Also, coagulopathy can be contributed by impaired wound healing or impaired clot formation.

<span class="mw-page-title-main">Desmopressin</span> Medication

Desmopressin, sold under the trade name DDAVP among others, is a medication used to treat diabetes insipidus, bedwetting, hemophilia A, von Willebrand disease, and high blood urea levels. In hemophilia A and von Willebrand disease, it should only be used for mild to moderate cases. It may be given in the nose, by injection into a vein, by mouth, or under the tongue.

<span class="mw-page-title-main">Glanzmann's thrombasthenia</span> Medical condition

Glanzmann's thrombasthenia is an abnormality of the platelets. It is an extremely rare coagulopathy, in which the platelets contain defective or low levels of glycoprotein IIb/IIIa (GpIIb/IIIa), which is a receptor for fibrinogen. As a result, no fibrinogen bridging of platelets to other platelets can occur, and the bleeding time is significantly prolonged.

Congenital afibrinogenemia is a rare, genetically inherited blood fibrinogen disorder in which the blood does not clot normally due to the lack of fibrinogen, a blood protein necessary for coagulation. This disorder is autosomal recessive, meaning that two unaffected parents can have a child with the disorder. The lack of fibrinogen expresses itself with excessive and, at times, uncontrollable bleeding.

<span class="mw-page-title-main">Bernard–Soulier syndrome</span> Medical condition

Bernard–Soulier syndrome (BSS) is a rare autosomal recessive bleeding disorder that is caused by a deficiency of the glycoprotein Ib-IX-V complex (GPIb-IX-V), the receptor for von Willebrand factor. The incidence of BSS is estimated to be less than 1 case per million persons, based on cases reported from Europe, North America, and Japan. BSS is a giant platelet disorder, meaning that it is characterized by abnormally large platelets.

<span class="mw-page-title-main">Ristocetin</span> Chemical compound

Ristocetin is a glycopeptide antibiotic, obtained from Amycolatopsis lurida, previously used to treat staphylococcal infections. It is no longer used clinically because it caused thrombocytopenia and platelet agglutination. It is now used solely to assay those functions in vitro in the diagnosis of conditions such as von Willebrand disease (vWD) and Bernard–Soulier syndrome. Platelet agglutination caused by ristocetin can occur only in the presence of von Willebrand factor multimers, so if ristocetin is added to blood lacking the factor, the platelets will not clump.

<span class="mw-page-title-main">GP1BA</span> Protein-coding gene in the species Homo sapiens

Platelet glycoprotein Ib alpha chain also known as glycoprotein Ib (platelet), alpha polypeptide or CD42b, is a protein that in humans is encoded by the GP1BA gene.

<span class="mw-page-title-main">Quebec platelet disorder</span> Medical condition

Quebec platelet disorder (QPD) is a rare autosomal dominant bleeding disorder first described in a family from the province of Quebec, Canada. The disorder is characterized by large amounts of the fibrinolytic enzyme urokinase-type plasminogen activator (uPA) in platelets. This causes accelerated fibrinolysis which can result in bleeding.

The ristocetin-induced platelet aggregation (RIPA) is an ex vivo assay for live platelet function. It measures platelet aggregation with the help of von Willebrand factor (vWF) and exogenous antibiotic ristocetin added in a graded fashion. It is similar to the ristocetin cofactor assay but has the added benefit in that it helps in the diagnosis of type 2B/pseudo von Willebrand disease (vWD) and Bernard–Soulier syndrome because it uses patient's live endogenous platelets, whereas ristocetin cofactor assay tests the function of only the vWF and not the platelets. Ristocetin cofactor assay uses the patient's platelet poor plasma and adds ristocetin and exogenous formalin-fixed platelets which can passively agglutinate. Formalin does not allow the extrinsic platelets to secrete the vWF of their α-granules, and thus only the activity of the intrinsic vWF is tested.

<span class="mw-page-title-main">Jeanne Lusher</span> American physician

Jeanne Marie Lusher, M.D. was an American physician, pediatric hematologist/oncologist, and a researcher in the field of bleeding disorders of childhood, and has served as the director of Hemostasis Program at the Children's Hospital of Michigan until her retirement on June 28, 2013.

<span class="mw-page-title-main">Upshaw–Schulman syndrome</span> Medical condition

Upshaw–Schulman syndrome (USS) is the recessively inherited form of thrombotic thrombocytopenic purpura (TTP), a rare and complex blood coagulation disease. USS is caused by the absence of the ADAMTS13 protease resulting in the persistence of ultra large von Willebrand factor multimers (ULVWF), causing episodes of acute thrombotic microangiopathy with disseminated multiple small vessel obstructions. These obstructions deprive downstream tissues from blood and oxygen, which can result in tissue damage and death. The presentation of an acute USS episode is variable but usually associated with thrombocytopenia, microangiopathic hemolytic anemia (MAHA) with schistocytes on the peripheral blood smear, fever and signs of ischemic organ damage in the brain, kidney and heart.

Factor XII deficiency is a deficiency in the production of factor XII (FXII), a plasma glycoprotein and clotting factor that participates in the coagulation cascade and activates factor XI. FXII appears to be not essential for blood clotting, as individuals with this condition are usually asymptomatic and form blood clots in vivo. FXII deficiency tends to be identified during presurgical laboratory screening for bleeding disorders.

References

  1. ↑ MedlinePlus Encyclopedia : Von Willebrand disease
  2. 1 2 Kaur V, Elghawy O, Deshpande S, Riley D (February 2024). "von Willebrand disease: A guide for the internist". Cleve Clin J Med. 91 (2): 119–127. doi:10.3949/ccjm.91a.22033. PMID   38307601.
  3. ↑ Swystun LL, James PD (January 2017). "Genetic diagnosis in hemophilia and von Willebrand disease". Blood Reviews. 31 (1): 47–56. doi:10.1016/j.blre.2016.08.003. PMID   27596108.
  4. ↑ Nichols WL, Hultin MB, James AH, Manco-Johnson MJ, Montgomery RR, Ortel TL, Rick ME, Sadler JE, Weinstein M, Yawn BP (March 2008). "von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)". Haemophilia. 14 (2): 171–232. doi: 10.1111/j.1365-2516.2007.01643.x . PMID   18315614.
  5. ↑ Lavin M, Aguila S, Schneppenheim S, Dalton N, Jones KL, O'Sullivan JM, O'Connell NM, Ryan K, White B, Byrne M, Rafferty M, Doyle MM, Nolan M, Preston RJ, Budde U, James P, Di Paola J, O'Donnell JS (November 2017). "Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels". Blood. 130 (21): 2344–53. doi:10.1182/blood-2017-05-786699. PMC   5881608 . PMID   28916584.
  6. 1 2 3 4 5 6 7 8 9 James PD, Connell NT, Ameer B, Di Paola J, Eikenboom J, Giraud N, et al. (2021-01-12). "ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease". Blood Advances. 5 (1): 280–300. doi:10.1182/bloodadvances.2020003265. ISSN   2473-9529. PMC   805340 . PMID   33570651.
  7. ↑ "Von Willebrand Disease". hemophilia.org. 4 March 2014. Retrieved 4 April 2018.
  8. 1 2 Connell NT, Flood VH, Brignardello-Petersen R, Abdul-Kadir R, Arapshian A, Couper S, et al. (2021-01-12). "ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease". Blood Advances. 5 (1): 301–325. doi:10.1182/bloodadvances.2020003264. PMC   805326 . PMID   33570647.
  9. ↑ Lavin M, Aguila S, Dalton N, Nolan M, Byrne M, Ryan K, White B, O'Connell NM, O'Sullivan JM, Di Paola J, James PD, O'Donnell JS (July 2018). "Significant gynecological bleeding in women with low von Willebrand factor levels". Blood Advances. 2 (14): 1784–91. doi:10.1182/bloodadvances.2018017418. PMC   6058240 . PMID   30042144.
  10. ↑ De Wee EM, Knol HM, Mauser-Bunschoten EP, van der Bom JG, Eikenboom JC, Fijnvandraat K, De Goede-Bolder A, Laros-van Gorkom B, Ypma PF, Zweegman S, Meijer K, Leebeek FW (November 2011). "Gynaecological and obstetric bleeding in moderate and severe von Willebrand disease" (PDF). Thrombosis and Haemostasis. 106 (5): 885–92. doi:10.1160/TH11-03-0180. PMID   21947221. S2CID   8677623.
  11. 1 2 3 4 National Hemophilia Federation (2014-03-05). "Von Willebrand Disease". National Hemophilia Federation. Retrieved 3 December 2017.
  12. 1 2 3 4 5 Karen A. Moser; George M. Rodgers III; Kristi J. Smock. "Von Willebrand Disease - VWD". ARUP laboratories. Last Update: July 2020. Content Review: June 2020
  13. ↑ Chornenki NL, Ocran E, James PD (December 2022). "Special considerations in GI bleeding in VWD patients". Hematology Am Soc Hematol Educ Program. 2022 (1): 624–630. doi:10.1182/hematology.2022000390. PMC   9820382 . PMID   36485078.
  14. ↑ James PD, Notley C, Hegadorn C, Leggo J, Tuttle A, Tinlin S, Brown C, Andrews C, Labelle A, Chirinian Y, O'Brien L, Othman M, Rivard G, Rapson D, Hough C, Lillicrap D (January 2007). "The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study". Blood. 109 (1): 145–54. doi: 10.1182/blood-2006-05-021105 . PMID   17190853.
  15. ↑ Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ, Montgomery RR (June 1987). "The effect of ABO blood group on the diagnosis of von Willebrand disease". Blood. 69 (6): 1691–5. doi: 10.1182/blood.V69.6.1691.1691 . PMID   3495304.
  16. ↑ Boender J, Eikenboom J, van der Bom JG, Meijer K, de Meris J, Fijnvandraat K, Cnossen MH, Laros-van Gorkom BA, van Heerde WL, Mauser-Bunschoten EP, de Maat MP, Leebeek FW (December 2018). "Clinically relevant differences between assays for von Willebrand factor activity". J Thromb Haemost. 16 (12): 2413–24. doi:10.1111/jth.14319. PMID   30358069.
  17. 1 2 3 4 5 Borhany, Munira; Pahore, Zaen; ul Qadr, Zeeshan; Rehan, Muhammad; Naz, Arshi; Khan, Asif; Ansari, Saqib; Farzana, Tasneem; Nadeem, Muhammad; Raza, Syed Amir; Shamsi, Tahir (2010). "Bleeding disorders in the tribe: result of consanguineous in breeding". Orphanet Journal of Rare Diseases. 5 (1). doi: 10.1186/1750-1172-5-23 . ISSN   1750-1172. PMID   20822539.
  18. ↑ Swami A, Kaur V (November 2017). "von Willebrand Disease: A Concise Review and Update for the Practicing Physician". Clinical and Applied Thrombosis/Hemostasis. 23 (8): 900–910. doi: 10.1177/1076029616675969 . PMID   27920237.
  19. ↑ Lee, Christine A.; Kadir, Rezan A.; Kouides, Peter A. (2009). Inherited Bleeding Disorders in Women. Blackwell. doi:10.1002/9781444303490. ISBN   1-4051-6915-X.
  20. ↑ Favaloro EJ, Bonar R, Kershaw G, Sioufi J, Baker R, Hertzberg M, Street A, Marsden K (July 2006). "Reducing errors in identification of von Willebrand disease: the experience of the royal college of pathologists of australasia quality assurance program". Seminars in Thrombosis and Hemostasis. 32 (5): 505–13. doi:10.1055/s-2006-947865. PMID   16862524. S2CID   260321152.
  21. ↑ Chandler WL, Peerschke EI, Castellone DD, Meijer P (June 2011). "Von Willebrand factor assay proficiency testing. The North American Specialized Coagulation Laboratory Association experience". American Journal of Clinical Pathology. 135 (6): 862–9. doi: 10.1309/AJCPH5JK4ONENPAE . PMID   21571959.
  22. 1 2 3 Meiring, Muriel; Coetzee, Marius; Kelderman, Mareli; Badenhorst, Philip (2011). "Laboratory Diagnosis and Management of von Willebrand Disease in South Africa". Seminars in Thrombosis and Hemostasis. 37 (5): 576–580. doi:10.1055/s-0031-1281045. ISSN   0094-6176. PMID   22102202. S2CID   260318180.
  23. ↑ Seidizadeh O, Baronciani L, Lillicrap D, Peyvandi F (August 2024). "Application of genetic testing for the diagnosis of von Willebrand disease". J Thromb Haemost. 22 (8): 2115–28. doi:10.1016/j.jtha.2024.05.006. PMID   38762018.
  24. 1 2 Beltran A, Jaramillo AP, Vallejo MP, Acosta L, Barberan Parraga GC, Guanín Cabrera CL, Gaibor VG, Cueva MG (August 2023). "Desmopressin as a Treatment in Patients With Von Willebrand Disease: A Systematic Review". Cureus. 15 (8): e44310. doi: 10.7759/cureus.44310 . PMC   10464544 . PMID   37649925.
  25. ↑ Casonato A, Galletta E, Sarolo L, Daidone V (January 2018). "Type 2N von Willebrand disease: Characterization and diagnostic difficulties". Haemophilia. 24 (1): 134–140. doi:10.1111/hae.13366. PMID   29115006.
  26. 1 2 Unless otherwise specified in boxes, reference is: Margaret E Rick. "Clinical presentation and diagnosis of von Willebrand disease". UpToDate. Literature review current through: Jan 2021. This topic last updated: Feb 05, 2021. In turn adapted from The National Heart, Lung and Blood Institute. The Diagnosis, Evaluation, and management of Von Willebrand Disease. National Institutes of Health Publication 08-5832, December 2007
  27. ↑ Tiede A, Rand JH, Budde U, Ganser A, Federici AB (June 2011). "How I treat the acquired von Willebrand syndrome". Blood. 117 (25): 6777–85. doi:10.1182/blood-2010-11-297580. PMID   21540459.
  28. ↑ Vincentelli A, Susen S, Le Tourneau T, Six I, Fabre O, Juthier F, Bauters A, Decoene C, Goudemand J, Prat A, Jude B (July 2003). "Acquired von Willebrand syndrome in aortic stenosis". The New England Journal of Medicine. 349 (4): 343–9. doi: 10.1056/NEJMoa022831 . PMID   12878741.
  29. ↑ Uriel N, Pak SW, Jorde UP, Jude B, Susen S, Vincentelli A, Ennezat PV, Cappleman S, Naka Y, Mancini D (October 2010). "Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation". Journal of the American College of Cardiology. 56 (15): 1207–13. doi: 10.1016/j.jacc.2010.05.016 . PMID   20598466.
  30. ↑ Selmi C, La Marca A (December 2023). "Oral hormonal therapy as treatment option for abnormal uterine bleeding". Eur J Contracept Reprod Health Care. 28 (6): 285–294. doi:10.1080/13625187.2023.2270098. PMID   37955241.
  31. ↑ Wang L, Chen R, Tian F, Wang W, Wang L, Yu B, Huang X, Zhang Y, Su S, Ma G, Wang K (August 2016). "Life threatening biphasic adverse reactions to desmopressin: case report and review of the literature". Int J Clin Pharmacol Ther. 54 (8): 640–4. doi:10.5414/CP202461. PMID   27142268.
  32. ↑ Chandran R, Tohit ER, Stanslas J, Salim N, Mahmood TM, Rajagopal M (July 2024). "Shifting Paradigms and Arising Concerns in Severe Hemophilia A Treatment". Semin Thromb Hemost. 50 (5): 695–713. doi:10.1055/s-0043-1778103. PMID   38224699.
  33. ↑ Othman M, Gresele P (August 2020). "Guidance on the diagnosis and management of platelet-type von Willebrand disease: A communication from the Platelet Physiology Subcommittee of the ISTH". J Thromb Haemost. 18 (8): 1855–8. doi:10.1111/jth.14827. PMID   32279414.
  34. ↑ "Vonvendi (von willebrand factor- recombinant kit". DailyMed. 13 February 2019. Retrieved 27 March 2020.
  35. ↑ "Veyvondi EPAR". European Medicines Agency (EMA). 20 September 2018. Retrieved 27 March 2020.
  36. ↑ Peyvandi F, Kouides P, Turecek PL, Dow E, Berntorp E (November 2019). "Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor". Blood Rev. 38: 100572. doi:10.1016/j.blre.2019.04.001. PMID   31229334.
  37. 1 2 "Molecular basis of von Willebrand disease and its clinical implications". Haematologica. 89 (9): 1036. September 2004. PMID   15377463. Archived from the original on 2011-10-02. Retrieved 2009-01-30.
  38. ↑ Keohane, Elaine; Otto, Catherine; Walenga, Jeanine (2020). Rodak's Hematology: Clinical Principles and Applications (6th ed.). St Louism Missouri: Elsevier. p. 662. ISBN   978-0-323-53045-3. OCLC   1229771843.
  39. ↑ Von Willebrand EA (May 1999). "Hereditary pseudohaemophilia". Haemophilia. 5 (3): 223–31, discussion 222. doi:10.1046/j.1365-2516.1999.00302.x. PMID   10444294. S2CID   221750622.
  40. ↑ Beighton P, Beighton G (2012). "Portraits and Biographies". The Man Behind the Syndrome. Springer. pp. 1–201 See p. 187. doi:10.1007/978-1-4471-1415-4_1. ISBN   978-1-4471-1415-4.
  41. ↑ Lassila R, Lindberg O (2013). "Erik von Willebrand" (PDF). Haemophilia. 19 (5): S3–S4. doi:10.1016/J.THROMRES.2007.03.010. PMID   23980590. S2CID   11256355. Archived from the original (PDF) on 2018-06-20.
  42. ↑ "Canine von Willebrand Disease - Breed Summaries". ahdc.vet.cornell.edu. 2019-02-08.
  43. ↑ "Canine von Willebrand Disease". vetgen.com.
  44. ↑ Lehner S, Ekhlasi-Hundrieser M, Detering C, Allerkamp H, Pfarrer C, von Depka Prondzinski M (February 2018). "VWF Gene in Pigs Affected by Von Willebrand Disease Type 3". G3. 8 (2): 577–585. doi:10.1534/g3.117.300432. PMC   5919753 . PMID   29208651.
  45. ↑ Lozier JN, Nichols TC (April 2013). "Animal models of hemophilia and related bleeding disorders". Seminars in Hematology. 50 (2): 175–84. doi:10.1053/j.seminhematol.2013.03.023. PMC   3742033 . PMID   23956467.
  46. ↑ "Hemophilia A" (PDF). College of Dental Hygienists of Ontario. September 2, 2015.
  47. 1 2 Glick, Michael (2015). Burket's Oral Medicine. People's Medical. pp. 473, 475, 481, 482. ISBN   978-1-60795-188-9. OCLC   903962852.
  48. 1 2 Brewer, Andrew; Correa, Maria Elvira (May 2006). Guidelines for dental treatment of patients with inherited bleeding disorders (PDF) (Monograph). World Federation of Hemophilia. 40.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.